Since the abolition of government pricing in most of the drugs in 2015, the basis price of medical insurance payment has become an important means of controlling drug prices. At present, although some provinces have gradually implemented this policy , but there are still some problems in the implementation, on the one hand, grouping only by generic name and the basis price is the lowest tender price, thus will lead to "bad medicine to drive good medicine" due to the quality difference between the generic drugs and the original drug s .On the other hand, although the medical insurance department has encouraged enterprises to submit evidence of economic evaluation in negotiated pricing, the evaluation process is still to be standardized. In view of the above two aspects, this paper use abroad experience for reference and makes reasonable suggestions for the basis price and evaluation process in our country